Investigational Drug Information for Dapansutrile
✉ Email this page to a colleague
What is the development status for investigational drug Dapansutrile?
Dapansutrile is an investigational drug.
There have been 8 clinical trials for Dapansutrile.
The most recent clinical trial was a Phase 1 trial, which was initiated on November 1st 2025.
The most common disease conditions in clinical trials are Syndrome, Myocardial Infarction, and Heart Failure. The leading clinical trial sponsors are Olatec Therapeutics LLC, Van Andel Research Institute, and Radboud University.
There are fifty-seven US patents protecting this investigational drug and thirty-nine international patents.
Summary for Dapansutrile
| US Patents | 57 |
| International Patents | 39 |
| US Patent Applications | 207 |
| WIPO Patent Applications | 91 |
| Japanese Patent Applications | 6 |
| Clinical Trial Progress | Phase 1 (2025-11-01) |
| Vendors | 47 |
Recent Clinical Trials for Dapansutrile
| Title | Sponsor | Phase |
|---|---|---|
| A Trial to Test the Use of Dapansutrile, an Anti-inflammatory Medication, in People With Parkinson's Disease | Cure Parkinson's | PHASE2 |
| A Trial to Test the Use of Dapansutrile, an Anti-inflammatory Medication, in People With Parkinson's Disease | Olatec Therapeutics LLC | PHASE2 |
| A Trial to Test the Use of Dapansutrile, an Anti-inflammatory Medication, in People With Parkinson's Disease | University of Cambridge | PHASE2 |
Clinical Trial Summary for Dapansutrile
Top disease conditions for Dapansutrile
Top clinical trial sponsors for Dapansutrile
US Patents for Dapansutrile
| Drugname | Patent Number | Patent Title | Patent Assignee | Estimated Expiration |
|---|---|---|---|---|
| Dapansutrile | ⤷ Start Trial | 3-methanesulfonylpropionitrile for treating inflammation and/or pain | Olatec Therapeutics Inc | ⤷ Start Trial |
| Dapansutrile | ⤷ Start Trial | Deuterated 3-methanesulfonylpropionitrile | Olatec Therapeutics Inc | ⤷ Start Trial |
| Dapansutrile | ⤷ Start Trial | Electrolyte and lithium-ion battery containing the same | Contemporary Amperex Technology Hong Kong Ltd | ⤷ Start Trial |
| Dapansutrile | ⤷ Start Trial | Pharmaceutical composition | Olatec Therapeutics Inc | ⤷ Start Trial |
| Dapansutrile | ⤷ Start Trial | 3-methanesulfonylpropionitrile for treating inflammation and/or pain | Olatec Therapeutics Inc | ⤷ Start Trial |
| Dapansutrile | ⤷ Start Trial | Method for treating multiple sclerosis | Olatec Therapeutics Inc | ⤷ Start Trial |
| >Drugname | >Patent Number | >Patent Title | >Patent Assignee | >Estimated Expiration |
International Patents for Dapansutrile
| Drugname | Country | Document Number | Estimated Expiration | Related US Patent |
|---|---|---|---|---|
| Dapansutrile | Australia | AU2011344030 | 2030-12-15 | ⤷ Start Trial |
| Dapansutrile | Brazil | BR112013014583 | 2030-12-15 | ⤷ Start Trial |
| Dapansutrile | Canada | CA2820625 | 2030-12-15 | ⤷ Start Trial |
| Dapansutrile | China | CN103260613 | 2030-12-15 | ⤷ Start Trial |
| Dapansutrile | European Patent Office | EP2651407 | 2030-12-15 | ⤷ Start Trial |
| Dapansutrile | Japan | JP2014503533 | 2030-12-15 | ⤷ Start Trial |
| >Drugname | >Country | >Document Number | >Estimated Expiration | >Related US Patent |
